Catalog #CP115

RecombiMAb anti-mouse CCR6 (LALA-PG)

Clone C6Mab-13-CP115
Reactivities Mouse
Isotype Mouse IgG2a (LALA-PG), κ
(switched from Rat IgG1, κ)

$560.00 - $7,581.50

$560.00 - $7.00

Choose an Option...
  • 25 mg - $7,581.50
  • 5 mg - $2,170.50
  • 1 mg - $560.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left

Product Description

The C6Mab-13-CP115 monoclonal antibody is a recombinant, chimeric version of the original C6Mab-13 antibody. The variable domain sequences are identical but the constant region sequences have been switched from Rat IgG2b, κ to mouse IgG2a, κ for use in murine models. Additionally, C6Mab-13-CP115 contains LALA-PG mutations in the heavy chain Fc fragment rendering it unable to bind endogenous murine Fcγ receptors or C1q to induce antibody-dependent, cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). The LALA-PG variant has demonstrated significantly reduced effector function, C1q binding and C3 fixation compared to other common silencing mutations such as the LALA and DANG variants while retaining favorable biophysical and manufacturing properties. Species-matched chimeric antibodies demonstrate reduced immunogenicity and formation of anti-drug antibodies (ADAs) compared to xenogenic antibodies in animal models. The highly controlled sequence and lack of genetic drift in recombinant antibodies provide more reliable and reproducible results over hybridoma derived antibodies.

Mouse CCR6 (Ccr6) is a G protein–coupled chemokine receptor expressed on multiple immune cell subsets, including dendritic cells, B cells, and distinct T cell populations such as Th17 cells. It binds the chemokine CCL20 and directs cell trafficking to sites of inflammation, particularly in mucosal tissues like the gut and lung, where it contributes to host defense against microbes. Genetic disruption of CCR6 in mice leads to altered lymphocyte and dendritic cell localization and blunted inflammatory responses, highlighting its central role in shaping tissue immune microenvironments.

Specifications

Isotype Mouse IgG2a (LALA-PG), κ
Recommended Isotype Control(s) RecombiMAb mouse IgG2a (LALA-PG) isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Mutations LALA-PG
Immunogen mCCR6p1-19C peptide
Reported Applications Flow cytometry
For details on in vivo applications please contact technicalservice@bioxcell.com
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin ≤0.5EU/mg (≤0.0005EU/μg)
Determined by LAL assay
Aggregation* <5%
Determined by SEC
Purity ≥95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from mammalian cell supernatant in an animal-free facility
Purification Protein A
Molecular Weight 150 kDa
Murine Pathogen Tests Ectromelia/Mousepox Virus: Negative
Hantavirus: Negative
K Virus: Negative
Lactate Dehydrogenase-Elevating Virus: Negative
Lymphocytic Choriomeningitis virus: Negative
Mouse Adenovirus: Negative
Mouse Cytomegalovirus: Negative
Mouse Hepatitis Virus: Negative
Mouse Minute Virus: Negative
Mouse Norovirus: Negative
Mouse Parvovirus: Negative
Mouse Rotavirus: Negative
Mycoplasma Pulmonis: Negative
Pneumonia Virus of Mice: Negative
Polyoma Virus: Negative
Reovirus Screen: Negative
Sendai Virus: Negative
Theiler’s Murine Encephalomyelitis: Negative
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
Need a Custom Formulation? See All Antibody Customization Options
* Additional quality control measures for our InVivoPlusâ„¢ products include advanced binding validation, murine pathogen screening, protein aggregation screening, and ultra-low endotoxin levels. The superior quality of our InVivoPlusâ„¢ products will meet and exceed the strict demands and rigorous standards required for in vivo research. Learn more about the InVivoPlusâ„¢ difference here.

Product FAQs